2.210USDMkt Cap: 245.37M USDP/E: —Last update: 2026-05-22
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant m…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap245.37M USD
Enterprise Value73.40M USD
Revenue (TTM)18.42M USD
Gross Profit-88.86M USD
Net Income (TTM)-142.93M USD
Revenue/Share0.1740 USD
Last Price2.210 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees103
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0144421072
Valuation
P/E (Trailing)—
P/E (Forward)-3.16
PEG—
EV/EBITDA-0.58
EV/Revenue3.99
P/S13.32
P/B23.51
EPS (TTM)-1.19
EPS (Forward)-0.70
52W Range
2.17040% of range2.270
52W High2.270 USD
52W Low2.170 USD
Profitability
Gross Margin0.00%
Oper. Margin-2382.31%
EBITDA Margin0.00%
Profit Margin-679.16%
ROE-466.34%
ROA-48.74%
Growth
Revenue Growth-71.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-184.03M USD
CapEx (TTM)41.00K USD
FCF Margin-646.72%
FCF Yield-48.54%
Net Debt-171.97M USD
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity1.18
Current Ratio5.25
Quick Ratio5.04
Book Value/Sh0.0940 USD
Cash/Share1.860 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.6 (Hold)
Target (Mean)3.100 USD
Target Range1.000 USD – 6.000 USD
# Analysts5
Ownership
Shares Out.111.03M
Float94.09M
Insiders9.57%
Institutions84.06%
Short Interest
Short Ratio7.9d
Short % Float4.77%
Short % Out.4.50%
Shares Short5.00M
Short (prev mo.)6.28M
Technical
SMA 502.298 (-3.8%)
SMA 2002.111 (+4.7%)
Beta0.65
S&P 52W Chg28.31%
Avg Vol (30d)319.47K
Avg Vol (10d)732.69K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—